Medical Developments International Ltd (ASX: MVP) Share Price and News

Price

$0.62

Movement

0.00 (0.0)

as at 6 Jun - Closed (20 mins delayed)

52 Week Range

$0.37 - $0.94

 
1 Year Return

+44.66%

Medical Developments International Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $69.85 million
P/E Ratio 1,000.00
Dividend Yield 0.00%
Shares Outstanding 112.66 million
Earnings per share -0.336
Dividend per share 0.04
Year To Date Return 51.85%
Earnings Yield 0.10%
Franking 100%
Share Price

$0.62

Day Change

0.00 (0.0)

52 Week Range

$0.37 - $0.94

Yesterday's Close

$0.62

Today's Open

$0.63

Days Range

$0.595 - $0.63

Volume

258,034

Avg. Volume (1 month)

75,453

Turnover

$156,022

as at 6 Jun - Closed

  • Medical Developments International Ltd (ASX: MVP)
    Latest News

    a woman
    Investing

    Why I rate CogState Ltd shares a speculative buy

    CogState Ltd (ASX:CGS) is an under-the-radar small cap that may gain attention soon enough.

    Read more »

    a woman
    Investing

    How you can profit from 3 growing small caps revisited

    How have Pro Medicus Group Ltd (ASX:PME) and Medical Developments International Ltd (ASX:MVP) shares performed over the past year.

    Read more »

    a woman
    Investing

    Why these 4 ASX shares pushed higher today

    The Mayne Pharma Group Ltd (ASX:MYX) share price is one of four that climbed higher on Tuesday. Here's why...

    Read more »

    a woman
    Investing

    Medical Developments International Ltd's Chairman sells shares, time to worry?

    The Medical Developments International Ltd (ASX:MVP) Chairman has sold shares.

    Read more »

    a woman
    Investing

    3 shares I'd buy for diversification

    These 3 shares would be good for diversification.

    Read more »

    a woman
    Investing

    Medical Developments International Ltd crashes 5.4% on report

    Medical Developments International Ltd (ASX:MVP) disappoints shareholders.

    Read more »

    a woman
    Investing

    ALL ORDINARIES finishes lower Monday: 9 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished lower on Monday.

    Read more »

    a woman
    Investing

    Medical Developments International Ltd rises 3% on Walgreens deal

    Medical Developments International Ltd (ASX:MVP) has risen 4% in afternoon trade thanks to its Walgreens deal.

    Read more »

    a woman
    Investing

    3 shares that keep giving big returns

    Shareholders have been doing well from these shares…

    Read more »

    a woman
    Investing

    3 fast-growing healthcare shares to watch

    Nanosonics Ltd. (ASX:NAN) shares are one of three which I think investors should be watching closely…

    Read more »

    a woman
    Investing

    Why these 3 ASX shares just hit new all-time highs

    The Altium Limited (ASX:ALU) share price is one of three scaling new heights on Thursday. Here’s what you need to…

    Read more »

    a woman
    Investing

    The Medical Developments International Ltd share price is up 55% in 2017

    The Medical Developments International Ltd (ASX:MVP) share price continued its solid run on Tuesday, extending its year-to-date gain to 55%.

    Read more »

    Frequently Asked Questions

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Mar 2020 $0.0200 100.00% Interim 17 Apr 2020
    03 Sep 2019 $0.0200 100.00% Final 04 Oct 2019
    07 Mar 2019 $0.0200 100.00% Interim 17 Apr 2019
    30 Aug 2018 $0.0200 100.00% Final 05 Oct 2018
    02 Mar 2018 $0.0200 100.00% Interim 13 Apr 2018
    31 Aug 2017 $0.0000 100.00% Final 06 Oct 2017
    03 Mar 2017 $0.0200 100.00% Interim 10 Apr 2017
    01 Sep 2016 $0.0200 100.00% Final 07 Oct 2016
    02 Mar 2016 $0.0200 100.00% Interim 08 Apr 2016
    02 Sep 2013 $0.0200 100.00% Final 11 Oct 2013
    27 Feb 2013 $0.0300 100.00% Interim 11 Apr 2013
    28 Feb 2012 $0.0300 100.00% Interim 11 Apr 2012
    31 Aug 2011 $0.0300 100.00% Final 10 Oct 2011

    MVP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    2nd Jun 2025 2025-06-02T17:39:49 Notification regarding unquoted securities - MVPYesNo5:39pm617k
    30th May 2025 2025-05-30T10:04:48 Initial Director's Interest NoticeYesNo10:04am2235k
    30th May 2025 2025-05-30T09:10:18 Director Appointment and ResignationYesNo9:10am2221k
    29th Apr 2025 2025-04-29T09:19:26 Appendix 4C and Quarterly Activity Report - 31 March 2025YesNo9:19am8307k
    1st Apr 2025 2025-04-01T09:51:25 Initial Director's Interest Notice - M. FladrichYesNo9:51am2236k
    21st Mar 2025 2025-03-21T12:26:01 Appointment of Director - Mark FladrichYesNo12:26pm2220k
    20th Feb 2025 2025-02-20T08:22:34 FY25 Half Year AnnouncementYesNo8:22am3235k
    20th Feb 2025 2025-02-20T08:21:54 FY25 Half Year PresentationYesNo8:21am199.1M
    20th Feb 2025 2025-02-20T08:21:39 FY25 Half Year Report (including Appendix 4D)YesNo8:21am231.6M
    12th Feb 2025 2025-02-12T12:47:29 FY25 Half Year Results Announcement DetailsYesNo12:47pm1201k

    About Medical Developments International Ltd

    Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.

    The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries. 

     

     

    MVP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    05 Jun 2025 $0.62 $0.01 1.63% 28,269 $0.62 $0.63 $0.61
    04 Jun 2025 $0.62 $0.02 3.36% 188,850 $0.61 $0.63 $0.59
    03 Jun 2025 $0.60 $-0.08 -11.94% 42,004 $0.64 $0.64 $0.60
    02 Jun 2025 $0.67 $0.02 3.08% 59,579 $0.65 $0.67 $0.65
    30 May 2025 $0.65 $0.00 0.00% 45,508 $0.65 $0.67 $0.65
    29 May 2025 $0.65 $0.01 1.56% 118,725 $0.64 $0.70 $0.63
    28 May 2025 $0.64 $0.04 6.67% 61,569 $0.60 $0.64 $0.59
    27 May 2025 $0.60 $0.00 0.00% 52,696 $0.61 $0.61 $0.59
    26 May 2025 $0.60 $-0.02 -3.23% 28,329 $0.61 $0.61 $0.60
    23 May 2025 $0.62 $0.01 1.64% 46,033 $0.62 $0.62 $0.59
    22 May 2025 $0.61 $0.03 5.17% 82,106 $0.58 $0.61 $0.58
    21 May 2025 $0.58 $0.03 5.45% 46,753 $0.58 $0.58 $0.55
    20 May 2025 $0.55 $-0.02 -3.48% 62,947 $0.57 $0.57 $0.54
    19 May 2025 $0.58 $-0.02 -3.36% 23,940 $0.57 $0.59 $0.57
    16 May 2025 $0.60 $0.01 1.71% 109,375 $0.57 $0.61 $0.57
    15 May 2025 $0.59 $-0.01 -1.68% 105,838 $0.59 $0.61 $0.56
    14 May 2025 $0.60 $-0.02 -3.25% 35,118 $0.62 $0.63 $0.59
    13 May 2025 $0.62 $-0.01 -1.61% 71,123 $0.62 $0.63 $0.61
    12 May 2025 $0.62 $-0.02 -3.13% 64,672 $0.64 $0.67 $0.62
    09 May 2025 $0.64 $0.02 3.23% 116,752 $0.62 $0.65 $0.62
    08 May 2025 $0.62 $0.00 0.00% 25,734 $0.61 $0.62 $0.61
    07 May 2025 $0.62 $0.00 0.00% 157,502 $0.63 $0.63 $0.59
    06 May 2025 $0.62 $0.01 1.63% 161,994 $0.61 $0.63 $0.59

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Aug 2024 Christine Emmanuel-Donnelly Buy 26,478 $10,061
    As advised by the company. Participation in capital Raise
    28 Aug 2024 Gordon Naylor Issued 264,782 $100,617
    Rights issue.
    06 Aug 2024 Russell Basser Buy 2,160 $820
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Gordon Naylor Buy 93,453 $35,512
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Leon Hoare Buy 8,436 $3,205
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Richard Betts Buy 3,181 $1,208
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Maria (Mary) Sontrop Buy 2,801 $1,064
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Christine Emmanuel-Donnelly Buy 7,684 $2,919
    As advised by the company. Participation in capital Raise

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Leon Hoare Non-Executive Director Sep 2013
    Mr Hoare is a commercial leader with expertise across multiple Life Science sectors. Previously, he was Managing Director of Smith & Nephew (S&N) ANZ, one of S&N's largest global subsidiaries outside the USA. He served as President of S&N's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division (as one of three Regional Presidents). In his 24 years with S&N, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb, and as Vice-Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the Chair of the Human Resources Committee. He is member of Human Resource Committee.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO's IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne. She is member of Risk Committee.
    Mr Gordon Naylor Non-Executive DirectorNon-Executive Chairman Oct 2020
    Mr Naylor for over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. He is member of Human Resource and Continuous Disclosure Committee.
    Mr Paul Townsend Non-Executive Director May 2025
    Mr Townsend is a finance leader with industry experience across organisations spanning manufacturing, academic, resources, business-to-business, and consumer product sectors. His track record includes capital raisings, start-ups and mergers and acquisitions across both local and global markets, navigating both equity and debt capital markets and implementing changes necessary to deliver earnings growth, robust cash flow, and balance sheet optimisation. During his executive career, Paul was most recently CFO of Nufarm, an ASX listed global developer and manufacturer of crop protection solutions and seed technologies. Paul previous CFO roles include Monash University, ASX listed Aseleo Care Limited and Pacific Hydro Pty Ltd.
    Dr Russell Basser Non-Executive Director Aug 2023
    Dr Basser is a physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has expertise in international drug and vaccine development and spent several years based in the USA. He is member of Human Resource Committee.
    Mr Mark Fladrich Non-Executive Director Apr 2025
    Mr Fladrich brings experience to MVP with over 30 years in the pharmaceutical industry. His background includes senior leadership roles at global companies. During his executive career, Mark was most recently Chief Commercial Officer of Grunenthal, a mid-sized privately owned German company specialising in pain management.In his 23 years at AstraZeneca, Mark held several senior roles including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Prior to joining AstraZeneca, Mark held various roles at Allergan (now part of AbbVie Inc) and Faulding Pharmaceuticals in Australia. Mark is the Chair of QBiotics, an Australian public unlisted life sciences company. Mark is also a Board Observer and Strategic Advisor at HealthMatch, a Sydney based digital startup matching patients with clinical trials, and Chair of the Strategic Advisory Board for Atacana, a global pharmaceutical and biotech industry consulting firm.
    Mr Brent MacGregor Chief Executive Officer Nov 2020
    -
    Ms Tara Eaton Company SecretaryGeneral Counsel Aug 2022
    -
    A James CFO
    -
    Brent MacGregor Chief Executive Officer
    -
    Tara Eaton Company SecretaryGeneral Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 10,683,815 9.48%
    Citicorp Nominees Pty Limited 7,576,013 6.72%
    HSBC Custody Nominees (Australia) Limited 6,500,532 5.77%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 5,904,120 5.24%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 5,278,615 4.69%
    Ubs Nominees Pty Ltd 4,920,177 4.37%
    Netwealth Investments Limited <Wrap Services A/C> 3,650,550 3.24%
    Payne Media Pty Ltd 2,937,127 2.61%
    Mirrabooka Investments Limited 2,592,084 2.30%
    Dr Russell Kay Hancock 2,120,000 1.88%
    HSBC Custody Nominees (Australia) Limited A/C 2 1,367,424 1.21%
    BNP Paribas Nominees Pty Ltd <Clearstream> 1,364,260 1.21%
    Naylor Stewart Investments Pty Ltd <Naylor Stewart Family A/C> 1,045,113 0.93%
    Kidder Peabody Pty Ltd 1,042,945 0.93%
    Merrill Lynch (Australia) Nominees Pty Limited 867,848 0.77%
    Mr David Williams <William Street A/C> 861,817 0.76%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 861,039 0.76%
    Mr Alistair David Strong 750,000 0.67%
    National Nominees Limited 748,009 0.66%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 733,300 0.65%

    Profile

    since

    Note